Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Lenalidomide.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Lenalidomide.
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Lenalidomide.
Advertisement
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Anthrax immune globulin human.
Apalutamide
The serum concentration of Lenalidomide can be decreased when it is combined with Apalutamide.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Lenalidomide.
Advertisement
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Bacillus calmette-guerin substrain tice live antigen.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Lenalidomide.
Advertisement
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Lenalidomide.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lenalidomide.
Chlorotrianisene
Chlorotrianisene may increase the thrombogenic activities of Lenalidomide.
Clozapine
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Clozapine.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Lenalidomide.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Lenalidomide.
Darbepoetin Alfa
Darbepoetin alfa may increase the thrombogenic activities of Lenalidomide.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Lenalidomide.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Lenalidomide.
Dexamethasone
Dexamethasone may increase the thrombogenic activities of Lenalidomide.
Dienestrol
Dienestrol may increase the thrombogenic activities of Lenalidomide.
Diethylstilbestrol
Diethylstilbestrol may increase the thrombogenic activities of Lenalidomide.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Lenalidomide.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Lenalidomide.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Lenalidomide.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Lenalidomide.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Lenalidomide.
Epoetin Alfa
Erythropoietin may increase the thrombogenic activities of Lenalidomide.
Epoetin Alfa-Epbx
Erythropoietin may increase the thrombogenic activities of Lenalidomide.
Epoetin Beta
Erythropoietin may increase the thrombogenic activities of Lenalidomide.
Equol, (-)-
Equol may increase the thrombogenic activities of Lenalidomide.
Estradiol
Estradiol may increase the thrombogenic activities of Lenalidomide.
Estradiol acetate
Estradiol acetate may increase the thrombogenic activities of Lenalidomide.
Estradiol Cypionate
Estradiol cypionate may increase the thrombogenic activities of Lenalidomide.
Estradiol Valerate
Estradiol valerate may increase the thrombogenic activities of Lenalidomide.
Estriol
Estriol may increase the thrombogenic activities of Lenalidomide.
Estrogens, Conjugated (USP)
Conjugated estrogens may increase the thrombogenic activities of Lenalidomide.
Estrogens, Esterified (USP)
Estrogens, esterified may increase the thrombogenic activities of Lenalidomide.
Estrone
Estrone may increase the thrombogenic activities of Lenalidomide.
Ethinyl Estradiol
Ethinyl Estradiol may increase the thrombogenic activities of Lenalidomide.
Fingolimod
Lenalidomide may increase the immunosuppressive activities of Fingolimod.
Genistein
Genistein may increase the thrombogenic activities of Lenalidomide.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Hepatitis B Vaccine (Recombinant).
Isavuconazole
The serum concentration of Lenalidomide can be increased when it is combined with Isavuconazole.
Leflunomide
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Leflunomide.
Lumacaftor
The serum concentration of Lenalidomide can be decreased when it is combined with Lumacaftor.
Mestranol
Mestranol may increase the thrombogenic activities of Lenalidomide.
Methoxy polyethylene glycol-epoetin beta
Methoxy polyethylene glycol-epoetin beta may increase the thrombogenic activities of Lenalidomide.
Natalizumab
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Natalizumab.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Lenalidomide.
Ouabain
Ouabain may decrease the cardiotoxic activities of Lenalidomide.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Lenalidomide.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Lenalidomide.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lenalidomide.
Polyestradiol Phosphate
Polyestradiol phosphate may increase the thrombogenic activities of Lenalidomide.
Promestriene
Promestriene may increase the thrombogenic activities of Lenalidomide.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Lenalidomide.
Quinestrol
Quinestrol may increase the thrombogenic activities of Lenalidomide.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Lenalidomide.
Ranolazine
The serum concentration of Lenalidomide can be increased when it is combined with Ranolazine.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Lenalidomide.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Rubella virus vaccine.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Salmonella typhi ty21a live antigen.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Lenalidomide.
synthetic conjugated estrogens, A
Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Lenalidomide.
synthetic conjugated estrogens, B
Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lenalidomide.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Lenalidomide.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tibolone
Tibolone may increase the thrombogenic activities of Lenalidomide.
Tofacitinib
Lenalidomide may increase the immunosuppressive activities of Tofacitinib.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Lenalidomide.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Varicella Zoster Vaccine (Live/Attenuated).
Vemurafenib
The serum concentration of Lenalidomide can be increased when it is combined with Vemurafenib.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Yellow Fever Vaccine.
